Episode
LTR 147: Richard Matt on Bringing Benefit–Risk Upstream in Design and Development
- Podcast
- Let's Talk Risk! Podcast
- Published
- Mar 13, 2026
- Duration seconds
- 1616
- Processing state
not_requested
Actions
POST https://stenobird.com/v1/public/podcasts/let-s-talk-risk-podcast-6693844/episodes/ltr-147-richard-matt-on-bringing-benefit-risk-upstream-in-design-and-development/transcription-requests
Idempotently request low-priority transcript generation for this episode.GET https://stenobird.com/podcast/let-s-talk-risk-podcast-6693844/ltr-147-richard-matt-on-bringing-benefit-risk-upstream-in-design-and-development.md
Read the agent-friendly Markdown representation of this episode resource.
Summary
Summary “Look at how benefits and risks are allocated among different design options and pick a product architecture that minimizes risks and maximizes benefits.” In this Let’s Talk Risk! conversation , Richard Matt shares a simple but uncomfortable observation: most organizations do risk “correctly” on paper, but too late to matter. By the time the DFMEA/PFMEA is polished, key architecture decisions are already locked, so risk management becomes cleanup, not guidance. His most valuable takeaway is the shift upstream: start with the treatment plan, write down the expected benefits and plausible risks early, and iterate them as the design evolves. When benefits are made explicit, you stop treating risk as a single independent variable and start using benefit–risk as a practical decision engine for design tradeoffs. Listen to the full 30-minute podcast or jump to a section of interest listed below. Chapters 00:00 Welcome and Introduction 01:04 Risk focus in QMSR 04:50 Risk as an input to design 05:33 Why FMEA alone is not sufficient 10:33 Consider both benefits and risks early in design 20:43 Audience questions 24:30 Closing remarks If you enjoyed this podcast, consider subscribing to the Let’s Talk Risk! newsletter . Suggested links: LTR: Allison Komiyama on Rethinking Benefit-Risk in MedTech . LTR: Benefit-Risk Evaluation of an AI/ML Enabled Device . LTR: An Ideal Medical Device . Key Takeaways * Use benefit–risk early, not as an afterthought. Start at the treatment-plan/concept phase so benefit and harm shape architecture decisions before they’re hard to change. * Make “benefit” explicit and usable. If you only optimize against harm, you can unintentionally degrade clinical value; benefit must be part of the design tradeoff logic from day one. * FMEA is necessary, but…